FAB classification of myelodysplastic syndromes: merits and controversies

Annals of Hematology

Volumn 71, Issue 1, 1995, Pages 3-11

  Verhoef, G E G ^a   Pittaluga, S ^a   De Wolf Peeters, C ^a   Boogaerts, M A ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Clonality; CMML; FAB; Fibrosis; Myelodysplasia; Myeloproliferative disorders

Indexed keywords

BLOOD ANALYSIS; BONE MARROW; CYTOGENETICS; DISEASE CLASSIFICATION; FRANCE; HISTOLOGY; HUMAN; INTERNATIONAL COOPERATION; MYELODYSPLASTIC SYNDROME; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; UNITED KINGDOM; UNITED STATES;

BIOPSY; GENETIC TECHNIQUES; HUMAN; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 0029096820     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/BF01696227     Document Type: Review

References (68)

1. Clonality of cell populations in refractory anaemia using combined approach of gene loss and X-linked restriction fragment length polymorphismmethylation analyses
2. Chronic myelomonocytic leukemia: clinical features, cytogenetics, and prognosis in 30 consecutive patients
3. Detection of minimal residual disease state in chronic myelogenous leukemia patients using fluorescence in situ hybridization
4. Direct correlation of cytogenetic findings with cell morphology using in situ hybridization: an analysis of suspicious cells in bone marrow specimens of two patients completing therapy for acute lymphoblastic leukemia
5. Analysis of N-RAS exon-1 mutations in myelodysplastic syndromes by polymerase chain reaction and direct sequencing
6. Proposals for the classification of the myelodysplastic syndromes
7. The chronic myeloid leukaemias: guidelines for distinguishing granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaumia Group
8. Bone marrow karyotype and prognosis in primary myelodysplastic syndromes
9. Detection of chromosome aberrations in the human interphase nucleus by visualization of specific target DNAs with radioactive and non-radioactive in situ hybridization techniques: diagnosis of trisomy 18 with probe L1.84
10. Clonal lymphocytes are detectable in only some cases of MDS
11. Histopathology of myelodysplastic syndromes: the FAB classification (proposals) applied to bone marrow biopsy
12. Aplastic anaemia and the hypocellular myelodysplastic syndrome: histomorphological, diagnostic and prognostic features
13. Prognostic factors in chronic myelodysplastic syndromes: a multivariate analysis in 107 cases
14. Mammalian X-chromosome inactivation
15. Clonal analysis of myelodysplastic syndrome: monosomy 7 is expressed in the myeloid lineage, but not in the lymphoid lineage as detected by fluorescent in situ hybridization
16. Prognostic value of clonal chromosomal abnormalities in patients with primary myelodysplastic syndromes
17. A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome
18. Relation between an activated N-ras oncogene and chromosomal abnormality during leukemic progression from myelodysplastic syndrome
19. RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia
20. Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes
21. Genetic lesions in preleukemia
22. Ras gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes
23. Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin
24. Monosomy 7 in granulocytes and monocytes in myelodysplastic syndrome
25. Utility of the FAB classification for myelodysplastic syndromes. Investigation of prognostic factors in 256 cases
26. Myeloid but not lymphoid cells carry the 5q deletion: polymerase chain reaction analysis of loss of heterozygosity using mini-repeat sequences on highly purified cell fractions
27. Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinicopathological entity
28. Mutations of the Kirsten-ras proto-oncogene in human preleukemia
29. Mutation of Ki-ras and N-ras oncogenes in myelodysplastic syndromes
30. Ras activation in myelodysplastic syndromes: clinical and molecular study of the chronic phase of the disease
31. High la (HLA-DR) and low CD11b (Mo1) expression may predict early conversion to leukemia in myelodysplastic syndromes
32. Myelodysplastic syndromes: a scoring system with prognostic significance
33. Prognostic significance of single chromosome abnormalities in preleukemic states
34. Clinical and cytogenetic characteristics of myelodysplastic syndromes developing myelofibrosis
35. Ras mutations in myelodysplasia detected by amplification, oligonucleotide hybridization and transformation
36. Clinical cytogenetic correlations in myelodysplasia (preleukemia)
37. A common progenitor for human myeloid and lymphoid cells
38. Prognostic implications of bone marrow culturing in myelodysplastic syndrome: a retrospective analysis
39. FMS mutations in myelodysplastic, leukemic, and normal subjects
40. Bone marrow biopsy in myelodysplastic syndromes: morphological characterisitcs and contribution to the study of prognostic factors
41. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivate analysis of prognostic factors in 370 patients
42. The prognostic significance of Auer rods in myelodysplasia
43. Colony-stimulating factor-1 receptor
44. Results of chromosome studies and their relation to morphology, course and prognosis in 120 patients with de novo myelodysplastic syndromes
45. Circulating CD34 + cells: an adverse prognostic factor in the myelodysplastic syndromes
46. Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms
47. Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia
48. The myelodysplastic syndromes
49. Bone marrow histology in myelodysplastic syndromes. I. Histological findings in myelodysplastic syndromes and comparison with bone marrow smears
50. Bone marrow biopsy in the myelodysplastic syndromes. II. Prognostic value of abnormal localization of immature precursors in MDS
51. The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations
52. Prognostic patterns in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis
53. Clonality in myelodysplastic syndromes: demonstration of pluripotent stem cell origin using X-linked restriction fragment length polymorfisms
54. Myelodysplastic syndromes: a study of 101 cases to the FAB classification
55. Longitudinal analysis of point mutations of the N- ras protooncogene in patients with myelodysplasia using archived blood smears
56. Clonal involvement of granulocytes and monocytes, but not of T and B lymphocytes and natural killer cells in patients with myelodysplasia: analysis by X-linked restriction fragment length polymorphisms and polymerase chain reaction of the phosphoglycerate kinase gene
57. In situ hybridization on May-Grünwald Giemsa-stained bone marrow and blood smears of patients with hematologic disorders allow detection of cell-lineage-specific cytogenetic abnormalities
58. Point mutations of the N- ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogeous leukaemia
59. Update on the prognostic implication of morphology, histology, and karyotype in primary myelodysplastic syndromes
60. Myelodysplastic syndromes with bone marrow fibrosis: a myelodysplastic disorder with proliferative features
61. The myelodysplastic syndromes
62. Myelodysplastic syndromes evolving into a myeloproliferative disorder: one disease or two?
63. Use of restriction fragment length polymorphisms to determine the clonal origin of human tumours
64. Cytogenetic studies in 69 patients with myelodysplastic syndromes (MDS)
65. Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukemia
66. Mechanisms of ras mutations in myelodysplastic syndrome